购物车
- 全部删除
- 您的购物车当前为空
Src Inhibitor 1 (Src Kinase Inhibitor 1) 是一种选择性的、高效的、ATP-竞争性的双位点 Src 酪氨酸激酶抑制剂,能够抑制 Src (IC50:44 nM) 和 Lck (IC50:88 nM)。
为众多的药物研发团队赋能,
让新药发现更简单!
Src Inhibitor 1 (Src Kinase Inhibitor 1) 是一种选择性的、高效的、ATP-竞争性的双位点 Src 酪氨酸激酶抑制剂,能够抑制 Src (IC50:44 nM) 和 Lck (IC50:88 nM)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 279 | 现货 | |
2 mg | ¥ 393 | 现货 | |
5 mg | ¥ 578 | 现货 | |
10 mg | ¥ 788 | 现货 | |
25 mg | ¥ 1,830 | 现货 | |
50 mg | ¥ 2,950 | 现货 | |
100 mg | ¥ 4,350 | 现货 | |
500 mg | ¥ 9,130 | 现货 |
产品描述 | Src Inhibitor 1 (Src Kinase Inhibitor 1) is a potent and selective dual site Src tyrosine kinase inhibitor. |
靶点活性 | Lck:88nM, Src:44 nM |
体外活性 | Src-I1在激酶的ATP和肽结合位点具有竞争性作用。其IC50值对Src和Lck分别为44 nM和88 nM[1]。Src-I1是一种强效的Src抑制剂(IC50=0.18 μM),同时也能以类似Src的效力抑制Src家族的其他成员。此外,它对CHK2的抑制效力与对Src相当,而对Aurora B的抑制效力略低[2]。 |
激酶实验 | Assays (25.5 μL volume) are carried out robotically at room temperature (21°C) and are linear with respect to time and enzyme concentration under the conditions used. Assays are performed for 30 min using Multidrop Micro reagent dispensers in a 96-well format. The concentration of magnesium acetate in the assays is 10 mM and [γ-33P]ATP (800 c.p.m./pmol) is used at 5, 20 or 50 μM as indicated, in order to be at or below the Kmfor ATP for each enzyme.The assays are initiated with MgATP, stopped by the addition of 5 μL of 0.5 M orthophosphoric acid and spotted on to P81 filter plates using a unifilter harvester. The IC50 values of inhibitors are determined after carrying out assays at ten different concentrations of each compound[2]. |
别名 | Src-l1, Src Kinase Inhibitor 1 |
分子量 | 373.4 |
分子式 | C22H19N3O3 |
CAS No. | 179248-59-0 |
Smiles | N(C=1C2=C(C=C(OC)C(OC)=C2)N=CN1)C3=CC=C(OC4=CC=CC=C4)C=C3 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
溶解度信息 | DMSO: 3.73 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容